Tarčna terapija v zdravljenju raka pluč

Molekularna diagnotika v zdravljenju raka pljuč

Potencial in mesto zaviralcev EGFR na primeru bolnika

Potencial in mesto zaviralcev ALK na primeru bolnika

Vsebino izobraževanja si lahko ogledate na spodnjih predstavitvah.

<ol>
<li>Tan, Aaron C, and Daniel S W Tan. “Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 40,6 (2022): 611-625.</li>
<li>Hendriks, L E et al. “Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 34,4 (2023): 358-376.</li>
<li>Mok, T et al. “Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 31,8 (2020): 1056-1064.</li>
<li>Peters, Solange et al. “Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.” The New England journal of medicine vol. 377,9 (2017): 829-838.</li>
<li>Gadgeel, S et al. “Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.” Annals of oncology : official journal of the European Society for Medical Oncology vol. 29,11 (2018): 2214-2222.</li>
<li>Camidge, D Ross et al. “Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 38,31 (2020): 3592-3603.</li>
<li>Camidge, D Ross et al. “Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.” The New England journal of medicinevol. 379,21 (2018): 2027-2039.</li>
<li>Shaw, Alice T et al. “First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.” The New England journal of medicinevol. 383,21 (2020): 2018-2029.</li>
<li>Solomon, Benjamin J et al. “Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.” The Lancet. Respiratory medicine vol. 11,4 (2023): 354-366.</li>
<li>Kris, Mark G et al. “Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.” JAMA vol. 311,19 (2014): 1998-2006.</li>
<li>Howlader, Nadia et al. “The Effect of Advances in Lung-Cancer Treatment on Population Mortality.” The New England journal of medicine vol. 383,7 (2020): 640-649.</li>
<li>Herbst, Roy S et al. “Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 41,10 (2023): 1830-1840.</li>
<li>“<a href="https://www.gene.com/download/pdf/tarceva_prescribing.pdf" target="_blank" rel="noopener">TARCEVA (erlotinib) tablets, for oral use.</a>” Astellas Pharma US, Inc., and Genentech, Inc., 2016. Accessed on June 1st 2023.</li>
<li>“<a href="https://medicalinformation.astrazeneca-us.com/home/pdf-viewer.html?pdfPath=https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/4a362f01-597d-427f-937b-39d581aa82d7/4a362f01-597d-427f-937b-39d581aa82d7_source__v.pdf&amp;pdfTitle=IRESSA%20Digital%20Prescribing%20Information%20Placeholder&amp;documentNumber=promo_1170887&amp;productNames=IRESSA&amp;therapyAreas=oncology" target="_blank" rel="noopener">IRESSA (gefitinib) tablets for oral use.</a>” AstraZeneca, 2021. Revised in February 2023.</li>
<li>“<a href="http://content.boehringer-ingelheim.com/DAM/07c11f94-358a-439d-b0c8-af1e011f04c4/gilotrif-us-pi.pdf" target="_blank" rel="noopener">GILOTRIF (Afatinib Tablets), for Oral Use.</a>” Boehringer Ingelheim International GmbH, 2022. Revised in April 2022.</li>
<li>“<a href="https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/52503580-1192-44f7-a05e-5743159ed19b/52503580-1192-44f7-a05e-5743159ed19b_viewable_rendition__v.pdf" target="_blank" rel="noopener">TAGRISSO® (osimertinib) tablets, for oral use.</a>” AstraZeneca, 2022. Dostopano junij 2023. Revised in June 2023.</li>
<li>“<a href="https://labeling.pfizer.com/ShowLabeling.aspx?id=11019" target="_blank" rel="noopener">VIZIMPRO- dacomitinib tablet, film coated.</a>” Pfizer Laboratories Div Pfizer Inc, 2020. Revised in December 2020.</li>
<li>“<a href="https://www.exkivity.com/sites/default/files/2023-08/exkivity-prescribing-information.pdf" target="_blank" rel="noopener">EXKIVITY® (mobocertinib) capsules, for oral use</a>.” Takeda Pharmaceuticals U.S.A., Inc., 2021. Revised in September 2023.</li>
<li>Califano, R et al. “Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.” Drugsvol. 75,12 (2015): 1335-48.</li>
<li>Alexandrov, Ludmil B et al. “Signatures of mutational processes in human cancer.” Nature vol. 500,7463 (2013): 415-21. </li>
<li>Passiglia, Francesco et al. “Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.” British journal of cancer vol. 120,1 (2019): 57-62.</li>
</ol>

Avtor/ji

Opravite izobraževanje in pridobite kreditne točke

Tarčna terapija v zdravljenju raka pluč

Molekularna diagnotika v zdravljenju raka pljuč

Potencial in mesto zaviralcev EGFR na primeru bolnika

Potencial in mesto zaviralcev ALK na primeru bolnika

Reference

NOVO: Pregledovalnik interakcij zdravil